De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Soligenix Toekomstige groei

Future criteriumcontroles 2/6

De winst van Soligenix zal naar verwachting dalen met 1.5% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 75.8% per jaar. De winst per aandeel zal naar verwachting groeien met 16.7% per jaar.

Belangrijke informatie

-1.5%

Groei van de winst

16.7%

Groei van de winst per aandeel

Biotechs winstgroei	35.0%
Inkomstengroei	75.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	24 Apr 2023

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DB:DOA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	17	-14	N/A	N/A	1
12/31/2024	9	-15	N/A	N/A	2
12/31/2023	1	-16	N/A	N/A	2
12/31/2022	1	-14	-13	-13	N/A
9/30/2022	1	-15	-12	-12	N/A
6/30/2022	1	-15	-12	-12	N/A
3/31/2022	1	-15	-11	-11	N/A
12/31/2021	1	-13	-12	-12	N/A
9/30/2021	1	-13	-13	-13	N/A
6/30/2021	1	-12	-13	-13	N/A
3/31/2021	2	-12	-13	-13	N/A
12/31/2020	2	-18	-11	-11	N/A
9/30/2020	3	-15	-10	-10	N/A
6/30/2020	3	-16	-9	-9	N/A
3/31/2020	4	-15	-8	-8	N/A
12/31/2019	5	-9	-8	-8	N/A
9/30/2019	5	-10	-8	-8	N/A
6/30/2019	5	-9	-6	-6	N/A
3/31/2019	5	-8	-8	-8	N/A
12/31/2018	5	-9	-7	-7	N/A
9/30/2018	6	-8	-7	-7	N/A
6/30/2018	6	-7	-7	-7	N/A
3/31/2018	5	-8	-6	-6	N/A
12/31/2017	5	-7	-7	-7	N/A
9/30/2017	6	-5	-6	-6	N/A
6/30/2017	7	-6	-6	-6	N/A
3/31/2017	9	-4	-6	-6	N/A
12/31/2016	10	-3	-5	-5	N/A
9/30/2016	12	-5	N/A	-5	N/A
6/30/2016	13	-1	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat DOA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat DOA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat DOA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van DOA ( 75.8% per jaar) zal naar verwachting sneller groeien dan de markt German ( 5.4% per jaar).

Hoge groei-inkomsten: De omzet van DOA ( 75.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van DOA naar verwachting over 3 jaar hoog zal zijn

Soligenix Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Second quarter 2022 earnings released: US$0.055 loss per share (vs US$0.047 loss in 2Q 2021)

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.064 loss in 1Q 2021)

Insufficient new directors

No longer forecast to breakeven

Full year 2021 earnings released: US$0.31 loss per share (vs US$0.64 loss in FY 2020)

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)

Insufficient new directors

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven